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A B S T R A C T
Ceftazidime/avibactam comprises the broad-spectrum cephalosporin ceftazidime and the non-β-
lactam β-lactamase inhibitor avibactam. This phase 3, randomised, double-blind study (NCT01726023)
assessed the eﬃcacy and safety of ceftazidime/avibactam plus metronidazole compared with meropenem
in patients with complicated intra-abdominal infection (cIAI) in Asian countries. Subjects aged 18–90
years and hospitalised with cIAI requiring surgical intervention were randomised 1:1 to receive every
8 h either: ceftazidime/avibactam (2000/500 mg, 2-h infusion) followed by metronidazole (500 mg,
60-min infusion); or meropenem (1000 mg, 30-min infusion). Non-inferiority of ceftazidime/avibactam
plus metronidazole to meropenem was concluded if the lower limit of the 95% conﬁdence interval (CI)
for the between-group difference in clinical cure rate was greater than −12.5% at the test-of-cure (TOC)
visit (28–35 days after randomisation) in the clinically evaluable (CE) population. Safety was also
evaluated. Of 441 subjects randomised, 432 received at least one dose of study medication (ceftazidime/
avibactam plus metronidazole, n = 215; meropenem, n = 217). In the CE population at the TOC visit,
non-inferiority of ceftazidime/avibactam plus metronidazole to meropenem was demonstrated, with
clinical cure reported for 93.8% (166/177) and 94.0% (173/184) of subjects, respectively (between-
group difference, −0.2, 95% CI −5.53 to 4.97). The clinical cure rate with ceftazidime/avibactam plus
metronidazole was comparable in subjects with ceftazidime-non-susceptible and ceftazidime-
susceptible isolates (95.7% vs. 92.1%, respectively). Adverse events were similar between the study
groups. Ceftazidime/avibactam plus metronidazole was non-inferior to meropenem in the treatment of
cIAIs in Asian populations and was effective against ceftazidime-non-susceptible pathogens. No new
safety concerns were identiﬁed.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The prevalence and diversity of enteric bacteria producing
extended-spectrum β-lactamases (ESBLs) conferring resistance to
β-lactam antibiotics has become a global concern [1–3]. Compli-
cated intra-abdominal infections (cIAIs) are localised or diffuse
infections of the peritoneum caused by various conditions,
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including gastrointestinal perforation, necrosis of the gut wall spill-
ing bacteria, or dehiscence of bowel anastomoses [4]. Effective
treatment of cIAIs therefore requires both adequate source control
and empirical antimicrobial therapy that includes agents with an
extended spectrum of activity against Gram-negative as well as an-
aerobic pathogens [5,6].
The Study for Monitoring Antimicrobial Resistance Trends
(SMART) showed that ESBL-positive rates for Enterobacteriaceae iso-
lated from cIAIs were consistently highest in the Asia-Paciﬁc region
compared with the rest of the world from 2002 to 2011 [7].
Carbapenems have been used increasingly as a treatment option.
However, this trend has its own implications, with a notable in-
crease in carbapenemase-producing Enterobacteriaceae observed
across Asia [8,9].
Ceftazidime/avibactam comprises ceftazidime, an established
antipseudomonal cephalosporin, and avibactam, a ﬁrst-in-class non-
β-lactam β-lactamase inhibitor with activity against Ambler class A
[including ESBLs such as SHV, TEM and CTX-M, and Klebsiella
pneumoniae carbapenemase (KPC)], class C (AmpC) and some class
D (OXA-48) enzymes [10,11]. When tested in vitro, avibactam re-
stores the antimicrobial activity of ceftazidime, with ceftazidime/
avibactamdemonstrating reducedminimuminhibitoryconcentrations
(MICs) against various populations of ceftazidime-non-susceptible
Gram-negative bacteria, including some carbapenem-resistant En-
terobacteriaceae [11–14].
Ceftazidime/avibactamwas approved in 2015 by theUS Food and
Drug Administration (FDA) for the treatment of cIAI (in combination
with metronidazole) and complicated urinary tract infection (cUTI),
including acute pyelonephritis, in adults who have limited or no al-
ternative treatment options [15]. Approvalwas based in part on data
from two phase 2 trials in Western subjects (NCT00690378;
NCT00752219) [16,17] andhas been subsequently supported by data
from phase 3 trials in subjects in Western hospitals with
cIAI (NCT01499290; NCT01500239) [18], cUTI (NCT01595438;
NCT01599806) [19], or thosewitheither cIAI or cUTIwith ceftazidime-
non-susceptible Gram-negative infections (NCT01644643) [20]. An
additional phase 3 study in subjectswith nosocomial pneumonia, in-
cluding ventilator-associated pneumonia (VAP), has recently been
completed (NCT01808092).Data fromthesephase3programmescon-
tributed towards the recent approval by the European Medicines
Agency (EMA) of ceftazidime/avibactam for the treatment of adults
with cIAI, cUTI (including pyelonephritis), hospital-acquired pneu-
monia (includingVAP) and infectionsdue toGram-negativeorganisms
in patients with limited treatment options [21].
Potential pharmacokinetic and pharmacodynamic variation in
different ethnic groups owing to genetic and environmental factors
may affect the eﬃcacy and safety of a drug [22,23]. This is espe-
cially relevant when considering combination therapies, such as
ceftazidime/avibactam, in which it is essential that effective drug
concentrations of both elements are maintained. This phase 3 study
(NCT01726023) assessed the eﬃcacy and safety of ceftazidime/
avibactam plus metronidazole in patients hospitalised with cIAI in
a sample of Asian countries (China, Republic of Korea and Vietnam)
by determining the proportion of subjects assessed as clinical cure
after receiving ceftazidime/avibactam plus metronidazole com-
pared with those receiving meropenem.
2. Methods
2.1. Study design
RECLAIM 3 was a phase 3, multicentre, randomised, double-
blind, double-dummy, comparative study performed in China, the
Republic of Korea and Vietnam between January 2013 and March
2015. The study was conducted in accordance with Good Clinical
Practice guidelines and with the ethical principles that have their
origin in the Declaration of Helsinki. For each participating centre,
protocols (including all amendments) and informed consent docu-
ments were approved by an independent ethics committee and/
or institutional review board. To be eligible, all subjects or their legal
representatives had to provide informed written consent.
Subjects were randomised 1:1 to receive either ceftazidime/
avibactam 2000/500mg as a 2-h intravenous (i.v.) infusion followed
by metronidazole 500 mg as a 60-min i.v. infusion every 8 h, or
meropenem 1000 mg as a 30-min i.v. infusion every 8 h. Matching
placebo infusions were used to maintain blinding. For subjects with
moderate renal impairment [creatinine clearance (CrCL) 31–50mL/
min calculated using the Cockcroft–Gault method], dose regimen
adjustments were made to ceftazidime/avibactam 1000/250 mg
every 12 h and to meropenem 1000 mg every 12 h. No adjust-
ment for renal impairment was required for metronidazole.
Subjects were treated for a minimum of 5 days and for up to 14
days with i.v. study therapy. After 5 days, i.v. study therapy could
be stopped if clinical improvement was observed as judged by the
study investigator. Use of other systemic antibacterial treatments
was prohibited unless Enterococcus spp. ormethicillin-resistant Staph-
ylococcus aureus (MRSA) were among the pathogens suspected or
isolated. In this case, where available, subjects were permitted to
receive vancomycin, linezolid or daptomycin.
2.2. Subjects
This study included subjects aged 18–90 years and hospitalised
with cIAI requiring surgical intervention. Diagnosis was based on
clinical assessment, including intra-operative/laparoscopic ﬁnd-
ings within 24 h either side of randomisation (further details of cIAI
diagnosis are detailed in the Supplementary material). Microbio-
logical conﬁrmation was not a prerequisite.
Key exclusion criteria were diagnosis with traumatic bowel per-
forationundergoingsurgerywithin12h;perforationof gastroduodenal
ulcersundergoing surgerywithin24 h; abdominalwall abscess, bowel
obstructionor ischaemic bowelwithout perforation; intra-abdominal
processes in which the primary aetiology was not likely to be infec-
tive; simple cholecystitis or gangrenous cholecystitiswithout rupture;
simple appendicitis or acute suppurative cholangitis; necrotizingpan-
creatitis or pancreatic abscess; cIAI considered unlikely to respond
to 5–14days of antibiotic treatment; knownhistory of serious allergy
toβ-lactamantibioticsormetronidazole;andCrCL ≤30mL/min.Further
inclusion and exclusion criteria are provided in the Supplementary
material.
2.3. Procedures
After assessment for eligibility, patients were enrolled by the lead
investigator at each study centre. Randomisation to each treat-
ment group was performed according to a central randomisation
schedule, and computer-generated randomisation codes were as-
signed sequentially to eligible patients. These codes were assigned
by the unblinded pharmacist/designee of each centre using the in-
teractive voice response system/interactive web response system.
The same unblinded designee at each site prepared all of the blinded
i.v. study therapy according to the handling instructions. All other
personnel remained blinded to study therapy until ﬁnal unlocking
of the database, or in the case of a medical emergency.
Blood samples and specimens taken from the site of abdomi-
nal infection during surgery were collected for culture during
screening within 24 h prior to the ﬁrst dose of i.v. study therapy.
Susceptibility testing of the isolates against study drugs was per-
formed by the local laboratory using disk diffusionmethodology and
by the central laboratory using broth microdilution and disk dif-
fusion according to Clinical Laboratory Standards Institute (CLSI)
methodology and interpretive criteria where they exist [24]. Sub-
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jects with isolates typically not expected to respond to either study
drug (e.g. Acinetobacter spp. and Stenotrophomonas spp.) were ex-
cluded from the study.
Clinical response was determined by the investigators as clini-
cal cure, failure or indeterminate at the end-of-treatment (EOT)
(within 24 h following the last i.v. infusion of study therapy), test-
of-cure (TOC) (28–35 days after randomisation) and late follow-
up (LFU) (42–49 days after randomisation) visits. Clinical cure was
deﬁned as resolution or improvement in signs and symptoms of the
index infection so that no further treatment was required. Clinical
failure was deﬁned as any patients meeting the following criteria:
death related to IAI; persisting or recurrent infection within the
abdomen found at re-intervention either percutaneously or opera-
tively; post-surgical wound infections that required additional
antibiotics and/or non-routine wound care; additional antibiotics
for ongoing symptoms of IAI; and previously meeting criteria for
failure. Patients were classiﬁed as indeterminate if study data were
not available for evaluation of study drug eﬃcacy for any reason.
Adequacy of source control was assessed by an independent sur-
gical review panel (SRP) blinded to the study therapy. Clinical failures
with inadequate source control as assessed by the SRP were re-
classiﬁed as indeterminate.
2.4. Endpoints
Eﬃcacy endpoints were assessed in the analysis populations
shown in Table 1. The primary eﬃcacy endpoint was the clinical
cure rate at the TOC visit in clinically evaluable (CE) subjects. Key
secondary eﬃcacy endpoints reported here include clinical cure rate
in the CE population at the EOT and LFU visits; clinical cure rate at
the EOT, TOC and LFU visits in the microbiologically modiﬁed
intention-to-treat (mMITT), microbiologically evaluable (ME) and
extended ME (eME) populations; and clinical cure rate in subjects
with ceftazidime-non-susceptible pathogens (deﬁned by CLSI in-
terpretive criteria for both the resistant and intermediate categories:
ceftazidime MIC ≥ 8mg/L for Enterobacteriaceae and MIC ≥ 16mg/L
for Pseudomonas aeruginosa) in the eME population.
Adverse events (AEs) were assessed from time of screening up
to and including the LFU visit in the safety population. AEs were
summarised by preferred term and system organ class usingMedDRA
vocabulary (version 18.0).
At screening, baseline and throughout the study up to the LFU
visit, blood and urine samples were collected and were sent to a
central laboratory for haematology, clinical chemistry and urinal-
ysis; vital signs were monitored; and 12-lead electrocardiograms
(ECGs) were performed. CrCL was calculated at screening using
serum creatinine levels from the local laboratory.
2.5. Statistical analyses
For the primary endpoint of clinical cure rate in the CE popu-
lation at the TOC visit, non-inferiority of ceftazidime/avibactam plus
metronidazole compared with meropenem was concluded if the
lower limit of the 95% conﬁdence interval (CI) for the between-
group difference was greater than −12.5%. Between-group differences
and two-sided 95% CIs were determined using the unstratiﬁed
Miettinen & Nurminen method [25]. Sensitivity analyses with sub-
jects stratiﬁed by baseline severity of disease [Acute Physiology and
Table 1
Analysis populations and associated endpoints reported in the present study.
Population Deﬁnition Assessment
Modiﬁed intention-to-
treat (MITT)
Subjects met the disease deﬁnition of cIAI.
Subjects received at least one dose of study drug.
Baseline demographics and subject characteristics.
Clinically evaluable
(CE)
Subjects met the disease deﬁnition of cIAI. Subjects with a bacterial species not
expected to respond to both study drugs were excluded.
Subjects either received therapy for ≥48 h with 80% of the scheduled drug
administered; or received therapy for <48 h before discontinuing due to an AE.
Subjects were evaluated at the EOT, TOC or LFU visit with a clinical response of
cure or failure.
Subjects had no deviations from the protocol that would affect the assessment of
eﬃcacy.
Subjects did not receive any prior antibiotics other than protocol-speciﬁed
antibiotics with speciﬁed duration (see Supplementary material).
With the exception of metronidazole and protocol-speciﬁed antibiotics for the
coverage of Enterococcus spp. and MRSA (see exclusion criteria 3, Supplementary
material), subjects did not receive any concomitant antibiotic therapy from the
time of randomisation to the time of each assessment visit. This did not include
subjects with a response of clinical failure who required additional antibiotic
therapy. Topical antibacterials and antifungals were permitted as long as not
applied to the surgical site.
Subjects were considered to have received adequate initial source control of the
infection.
Primary endpoint: clinical cure rate at the TOC visit.
Secondary endpoints: clinical cure rate at the EOT and
LFU visits.
Microbiologically
modiﬁed intention-
to-treat (mMITT)
Subjects met the disease deﬁnition of cIAI.
Subjects had at least one aetiological pathogen identiﬁed at study entry. Those
with a bacterial species typically not expected to respond to both study drugs (e.g.
Acinetobacter spp., Stenotrophomonas spp.) were excluded.
Secondary endpoints: clinical cure rate at the EOT, TOC
and LFU visits.
Microbiologically
evaluable (ME)
Subjects met the criteria for the CE population.
Subjects had at least one Gram-negative pathogen in the pre-study culture that
was susceptible to both groups of study drugs.
Secondary endpoints: clinical cure rate at the EOT, TOC
and LFU visits.
Extended
microbiologically
evaluable (eME)
Subjects met the criteria for the CE population.
Subjects had at least one Gram-negative pathogen in the pre-study culture
regardless of susceptibility.
Secondary endpoints: clinical cure rate at the EOT, TOC
and LFU visits; and clinical cure rate at the TOC visit in
patients with infections caused by ceftazidime-non-
susceptible or ceftazidime-susceptible isolates.
Safety Subjects who received any amount of either study drug. Secondary endpoint: safety proﬁle of ceftazidime/
avibactam plus metronidazole compared with
meropenem.
cIAI, complicated intra-abdominal infection; AE, adverse event; EOT, end-of-treatment; TOC, test-of-cure; LFU, late-follow-up; MRSA, methicillin-resistant Staphylococcus
aureus.
CE, eME, ME and safety populations were analysed according to treatment received; MITT and mMITT were analysed according to randomisation group.
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Chronic Health Evaluation (APACHE) II score ≤10 or >10 and ≤30]
and country (China and non-China) were performed for the primary
eﬃcacy variable. Clinical outcome at the TOC visit in the CE pop-
ulation was also analysed by patient and disease baseline
characteristic subgroups. SAS® software v.9.1 or higher (SAS Insti-
tute, Inc., Cary, NC) was used to conduct all statistical analyses.
Study population size was designed to provide 80% power for a
−12.5% non-inferiority margin. Assuming that both treatment groups
had an underlying cure rate of 80% in the CE population, and that
80% of randomised subjects were included in the CE population, this
required 404 subjects (202 per treatment group) to be randomised,
with a minimum of 250 eligible subjects from China to adhere to
Chinese State Food and Drug Administration requirements.
3. Results
3.1. Patient disposition and baseline characteristics
Of the 486 subjects enrolled into the study, 441 subjects from
43 centres were randomised from 14 January 2013 to 30 January
2015. Of these, 270 (61.2%) were randomised in China, 105 (23.8%)
in the Republic of Korea and 66 (15.0%) in Vietnam. Overall, 432 sub-
jects received at least one dose of i.v. studymedication (ceftazidime/
avibactam plus metronidazole, n = 215; meropenem, n = 217) and
398 subjects completed treatment (ceftazidime/avibactam plusmet-
ronidazole, n = 196; meropenem, n = 202). The primary analysis
population (the CE population) comprised 177 and 184 subjects in
the ceftazidime/avibactam plus metronidazole group and
meropenem group, respectively (Fig. 1).
Baseline demographics and clinical characteristics in the modi-
ﬁed intention-to-treat (MITT) population (comprising subjects who
met the disease deﬁnition of cIAI and received at least one dose of
study drug) were generally balanced between treatment groups
(Table 2). The mean ± standard deviation duration of exposure to
i.v. study therapy in the safety population was 6.9 ± 2.9 days in the
ceftazidime/avibactam plus metronidazole group and 7.3 ± 2.8 days
in the meropenem group. Across both groups, 21.3% of subjects had
not received any systemic antimicrobial therapy in the 72 h prior
to randomisation. A further 65.4% had received <24 h of prior sys-
temic antimicrobial therapy (Table 2). Baseline characteristics in the
primary analysis population (the CE population) were generally com-
parable with those observed in the MITT population.
3.2. Pathogens at baseline
Baseline pathogens isolated from blood and/or the site of IAI were
similar across treatment arms. The proportions of patients with
monomicrobial and polymicrobial infections are summarised in
Table 2.
The mMITT population comprised 295 subjects, of whom 239
(81.0%) had one or more Enterobacteriaceae isolate identiﬁed from
the blood and/or intra-abdominal site. The most frequently re-
ported Enterobacteriaceae were Escherichia coli (173 subjects; 58.6%)
and K. pneumoniae (63 subjects; 21.4%). Of the 47 subjects (15.9%)
Fig. 1. Patient ﬂow. *Study treatment was stopped before receiving the minimum 5 days of treatment for any reason, or at any time and for any reason before the compli-
cated intra-abdominal infection was considered resolved or cured and a non-study antibiotic was required to complete treatment. †Primary analysis population comprising
all subjects who met the clinical disease criteria and who had an evaluable assessment and no deviations from the protocol that affected the assessment of eﬃcacy.
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with non-Enterobacteriaceae Gram-negative pathogens, P. aeruginosa
was the most frequently reported (37 subjects; 12.5%).
In themMITT population, 58 subjects (19.7%) split evenly between
the two treatment groups had an infection with a ceftazidime-non-
susceptible aerobic Gram-negative pathogen (ceftazidime
MIC ≥ 8 mg/L for Enterobacteriaceae and MIC ≥ 16 mg/L for P.
aeruginosa). Of these, 55 (18.6%) had ceftazidime-non-susceptible
Enterobacteriaceae isolates, including E. coli in 44 subjects
(ceftazidime/avibactam plus metronidazole, 19; meropenem, 25)
and K. pneumoniae in 4 (ceftazidime/avibactam plus metronida-
zole, 3; meropenem, 1). In addition, one P. aeruginosa isolate in the
ceftazidime/avibactam plus metronidazole group was non-
susceptible to ceftazidime.
For the 55 ceftazidime-non-susceptible Enterobacteriaceae, the
ceftazidime/avibactam MIC range was 0.03–4 mg/L, with an MIC90
of 1mg/L. The single ceftazidime-non-susceptible P. aeruginosa isolate
had a ceftazidime/avibactam MIC of 8 mg/L. Thus, among the
ceftazidime-non-susceptible isolates in the mMITT population, the
distribution of the ceftazidime/avibactam MICs was left-shifted to
a lower MIC compared with that of ceftazidime alone. In vitro, all
ceftazidime-non-susceptible isolates were within the susceptible
range for ceftazidime/avibactam.
In the mMITT population overall, one E. coli isolate in the
meropenem group had a meropenem MIC of 4 mg/L (meropenem
resistance deﬁned as MIC ≥ 2 mg/L for Enterobacteriaceae and
MIC ≥ 4 mg/L for P. aeruginosa). In addition, one K. pneumoniae
isolate in the meropenem group and three P. aeruginosa isolates
(ceftazidime/avibactam plus metronidazole, 1; meropenem, 2)
were resistant to meropenem. All four isolates that were resistant
to meropenem were within the susceptible range for
ceftazidime/avibactam.
Overall, Gram-positive aerobes were isolated in 73 subjects
(24.7%) in the mMITT population. The most frequent were Strepto-
coccus anginosus (15 subjects; 5.1%), Enterococcus faecalis (12 subjects;
4.1%), and Enterococcus faecium and Streptococcus mitis (11 sub-
jects each; 3.7%). At least one anaerobic pathogen was reported in
31 subjects (10.5%) in themMITT population, themost frequent being
Bacteroides fragilis (8 subjects; 2.7%).
3.3. Endpoints
Clinical cure at the TOC visit in the CE population was reported
in 166/177 (93.8%) of subjects receiving ceftazidime/avibactam plus
metronidazole and 173/184 (94.0%) of those receiving meropenem
(between-group difference, −0.2, 95% CI −5.53 to 4.97; P < 0.001)
(Fig. 2). This conﬁrmed the non-inferiority of ceftazidime/avibactam
versus meropenem. Sensitivity analyses conﬁrmed the robustness
of the primary analysis, with a difference in clinical cure rate in the
CE population at the TOC visit of 0.4% (95% CI −4.97 to 5.69), dem-
onstrating a consistent result with the primary eﬃcacy outcome
when stratiﬁed for baseline severity of disease and country. In the
CE population at the TOC visit, 11 patients in each treatment arm
were considered clinical failures. Reasons for clinical failure are
summarised in Supplementary Table S1.
Secondary endpoints were not formally assessed against a non-
inferioritymargin; however, clinical cure rate at theEOTandLFUvisits
in the CE population, aswell as the EOT, TOC and LFU visits in theME
andeMEpopulations, and theEOTvisit in themMITTpopulationwere
all similar to the primary analysis result, with the lower limit of the
95% CI for the between-group difference numerically above −12.5%
(Fig. 2). The differences in clinical cure rates between the two treat-
ment groupswere consistentwith the overall resultswhen analysed
by patient demographics and clinical characteristics (Fig. 3).
The treatment difference observed for clinical cure rate at TOC
and LFU visits in the mMITT population was greater than that in
the ME and eME populations (Fig. 2). Subjects in the mMITT pop-
ulation could be assessed as having an indeterminate response, which
was treated as a negative outcome. To conﬁrm this, a sensitivity anal-
ysis was performed to explore the impact of the indeterminate
outcomes by treating all subjects with indeterminate responses in
Table 2
Baseline patient and disease characteristics (modiﬁed intention-to-treat population)a.
Parameter Ceftazidime/avibactam +
metronidazole (n = 214)
Meropenem
(n = 217)
Age (years) (mean ± S.D.) 48.5 ± 16.8 48.5 ± 17.4
Sex male 141 (65.9) 153 (70.5)
Asian 214 (100) 217 (100)
Chinese 127 (59.3) 135 (62.2)
BMI (kg/m2) (mean ± S.D.) 22.7 ± 3.5 22.4 ± 3.5
APACHE II score
≤10 201 (93.9) 201 (92.6)
>10 to ≤30 13 (6.1) 16 (7.4)
Primary diagnosis
Appendiceal perforation or periappendiceal abscess 83 (38.8) 79 (36.4)
Secondary peritonitis 36 (16.8) 38 (17.5)
Cholecystitis 33 (15.4) 27 (12.4)
Intra-abdominal abscess 22 (10.3) 24 (11.1)
Acute gastric and duodenal perforations 22 (10.3) 23 (10.6)
Traumatic perforations 13 (6.1) 17 (7.8)
Diverticular disease 5 (2.3) 9 (4.1)
Prior treatment failure 26 (12.1) 27 (12.4)
Systemic antimicrobial therapy in the previous 72 h before randomisation 167 (78.0) 172 (79.3)
≤24 h exposure 139 (65.0) 143 (65.9)
Infection type
Monomicrobial infection 84 (39.3) 101 (46.5)
Polymicrobial infection 58 (27.1) 52 (24.0)
No study-qualifying pathogen identiﬁed 72 (33.6) 64 (29.5)
Bacteraemia 5 (2.3) 10 (4.6)
Renal status
Normal renal function/mild impairment (CrCL >50 mL/min) 201 (93.9) 201 (92.6)
Moderate impairment (CrCL >30 to ≤50 mL/min) 13 (6.1) 16 (7.4)
S.D., standard deviation; BMI, body mass index; APACHE, Acute Physiology and Chronic Health Evaluation; CrCL, creatinine clearance.
a Data are n (%) unless otherwise stated.
ARTICLE IN PRESS
Please cite this article in press as: Xinyu Qin, et al., A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus
meropenem for complicated intra-abdominal infections in hospitalised adults in Asia, International Journal of Antimicrobial Agents (2017), doi: 10.1016/j.ijantimicag.2017.01.010
5X. Qin et al. / International Journal of Antimicrobial Agents ■■ (2017) ■■–■■
the mMITT population as clinical cure. This resulted in similar re-
sponse rates between groups at the TOC visit [ceftazidime/avibactam
plus metronidazole, 133 (93.0%); meropenem, 143 (94.1%); differ-
ence, −1.1%, 95% CI −7.21 to 4.82].
Intra-abdominal culture requires an invasive procedure, which
was not performed during the follow-up period of the study. There-
fore, microbiological responses were presumed from clinical
responses for all subjects. In the ME and eME populations, the most
common Enterobacteriaceae species isolated in subjects in both treat-
ment groups was E. coli, and of these >90% of subjects in both groups
were assessed as clinical cure at the TOC visit.
There was no statistical evidence of a difference between treat-
ment groups in time to defervescence; however, the number of
patients in this analysis was small. No subjects in the ME, eME or
mMITT populations had emergent infections at the TOC visit.
Based on data from the eME population, ceftazidime/avibactam
was effective in treating infections caused by ceftazidime-non-
susceptible Gram-negative pathogens, with clinical cure rates similar
to those seen with ceftazidime-susceptible isolates [22/23 (95.7%)
vs. 70/76 (92.1%) subjects, respectively] (Table 3).
3.4. Surgical review panel ﬁndings
The SRP reviewed 34 subjects (ceftazidime/avibactam plus met-
ronidazole, 20; meropenem, 14) assessed by the investigator as
clinical failure. Six were considered to have inadequate source control
and were reassigned as indeterminate (ceftazidime/avibactam plus
metronidazole, 4; meropenem, 2). Furthermore, one patient in the
ceftazidime/avibactam plus metronidazole group who was as-
sessed by the investigator as clinical cure with a second procedure
was reassigned as indeterminate.
3.5. Safety
In the safety population, 82/215 (38.1%) and 83/217 (38.2%) sub-
jects in the ceftazidime/avibactam plus metronidazole and
meropenem groups, respectively, experienced at least one AE up to
the LFU visit. In both groups, ﬁve AEs (2.3%) were considered severe
in intensity. There were 9 (4.2%) and 11 (5.1%) serious AEs re-
ported in the ceftazidime/avibactam plus metronidazole and
meropenem groups, respectively. None of these were reported in
more than one patient in either treatment group. The most fre-
quently reported AEs were in the system organ class gastrointestinal
disorders [ceftazidime/avibactam plus metronidazole, 41 (19.1%);
meropenem, 26 (12.0%)], including nausea, diarrhoea, constipa-
tion and vomiting (Table 4).
The number of discontinuations due to AEs was low in both treat-
ment groups [ceftazidime/avibactam plus metronidazole, 7 (3.3%);
meropenem, 3 (1.4%)]. In the meropenem group, there was one AE
of aspiration pneumonia that commenced 28 days after the start
of treatment and resulted in death. This death was not considered
related to disease progression or to the study drug. There were also
two deaths due to disease progression in the ceftazidime/avibactam
plus metronidazole group, the primary causes of which were septic
shock andmulti-organ failure. Neither were considered to be related
to the study drug.
There were no clinically meaningful trends or concerns in vital
signs, ECGs, laboratory values or coagulation results.
4. Discussion
The data presented here contribute to the body of evidence sup-
porting the use of ceftazidime/avibactam in the treatment of patients
Fig. 2. Difference in clinical cure rate with ceftazidime/avibactam (CAZ-AVI) plus metronidazole compared with meropenem by visit and analysis population. CE, clinically
evaluable; EOT, end-of-treatment; TOC, test-of-cure; LFU, late follow-up; mMITT, microbiologically modiﬁed intention-to-treat; ME, microbiologically evaluable; CI, conﬁ-
dence interval. Data listed are n/N (%). Solid vertical line represents −12.5% non-inferiority margin.
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Fig. 3. Difference in clinical cure rates with ceftazidime/avibactam (CAZ-AVI) plus metronidazole compared with meropenem at test-of cure (TOC) visit in the clinically
evaluable (CE) population by (A) baseline demographics and (B) baseline clinical characteristics. CI, conﬁdence interval; APACHE, Acute Physiology and Chronic Health Eval-
uation; eCRF, electronic case report form; cIAI, complicated intra-abdominal infection; CrCL, creatinine clearance. Data listed are n/N (%).
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with cIAI by demonstrating that ceftazidime/avibactam in combi-
nation with metronidazole has equivalent eﬃcacy to meropenem
in patients hospitalised in China, the Republic of Korea and Vietnam.
Non-inferiority of ceftazidime/avibactam plus metronidazole was
demonstrated versus meropenem for the primary endpoint of clin-
ical cure at the TOC visit in the CE population, with the lower limit
of the 95% CI for the between-group difference being higher than
the pre-deﬁned margin of −12.5%. These ﬁndings are in line with
previous randomised controlled trials of other antimicrobials in
subjects with cIAI where non-inferiority to a ‘gold-standard’ com-
parator such as meropenem has been used to demonstrate
antimicrobial eﬃcacy [26–29].
To date, two phase 1 studies have shown the safety and phar-
macokinetics of ceftazidime/avibactam in healthy Chinese or
Japanese subjects to be comparable with that in healthy Western
subjects [30,31]. However, there has been little other clinical eval-
uation of ceftazidime/avibactam in an Asian-focused population. In
particular, there are no studies assessing the use of ceftazidime/
avibactam in the treatment of patients with cIAIs in Asian countries.
Interethnic differences in genotypic factors such as the expression
of metabolic enzymes and drug transporters as well as environ-
mental factors such as diet have the potential to affect the metabolic
proﬁle of a drug [22,23]. There is also the potential for variation in
clinical eﬃcacy due to regional differences in antimicrobial sus-
ceptibility [7]. The present study provides evidence that the eﬃcacy
and safety proﬁle of ceftazidime/avibactam in a distinct subset of
patients from the Asian region is consistent with previous data in
patients with cIAI from outside of Asia [18].
The differences in clinical cure rates between the two treat-
ment groups across patient demographic and clinical characteristic
subgroups, including age, APACHE II score and renal function, were
generally consistent with the primary results. The lower limit of the
95% CI for the between-group difference of clinical cure rate was
numerically greater than −12.5% at all time points assessed in each
of the secondary analysis populations, except for the mMITT pop-
ulation at the TOC and LFU visits. Here there was an observed
treatment difference in favour of meropenem that may be ex-
plained by the higher proportion of indeterminate responses in the
ceftazidime/avibactam plusmetronidazole group comparedwith the
meropenem group (Supplementary Table S2). This treatment dif-
ference was reﬂected in all subgroup analyses of the mMITT
population.
The pathogens isolated at baseline in the present studywere com-
parable with those isolated in the SMART surveillance study in 2008–
2009 in the Asia-Paciﬁc region and in other recent clinical studies
of cIAI, where the leading pathogens isolated from IAIs were E. coli
and K. pneumoniae [2,18,32]. The prevalence of P. aeruginosa in the
present study of patients enrolled in China, the Republic of Korea
and Vietnam was also consistent with that seen in subjects from
outside Asia [18]. In total, 19.7% of patients in the mMITT popula-
tion in the present study had a ceftazidime-non-susceptible aerobic
Gram-negative pathogen compared with 13.5% of patients in the
Table 3
Clinical response at the test-of-cure visit for subjects with ceftazidime-non-susceptible (CAZ-NS) and ceftazidime-susceptible (CAZ-S) Gram-negative pathogens [extended
microbiologically evaluable (eME) population].
Isolates Susceptibility Ceftazidime/avibactam + metronidazole (N = 100) Meropenem (N = 119) Comparison between groups
[differencea, % (95% CIb)]
n Clinical cure [n (%)] n Clinical cure [n (%)]
All isolates CAZ-NS 23 22 (95.7) 26 25 (96.2) −0.5 (−17.93, 15.43)
CAZ-S 76 70 (92.1) 89 84 (94.4) −2.3 (−11.30, 5.82)
Enterobacteriaceae CAZ-NS 21 20 (95.2) 25 24 (96.0) −0.8 (−19.51, 15.78)
CAZ-S 70 64 (91.4) 81 78 (96.3) −4.9 (−14.28, 3.08)
Escherichia coli CAZ-NS 14 13 (92.9) 23 22 (95.7) −2.8 (−28.19, 15.54)
CAZ-S 54 50 (92.6) 53 51 (96.2) −3.6 (−14.40, 6.40)
Klebsiella pneumoniae CAZ-NS 3 3 (100) 1 1 (100) 0.0 (−63.06, 83.67)
CAZ-S 16 15 (93.8) 26 25 (96.2) −2.4 (−25.36, 14.04)
Non-Enterobacteriaceae CAZ-NS 2 2 (100) 1 1 (100) 0.0 (−74.23, 85.21)
CAZ-S 15 15 (100) 15 13 (86.7) 13.3 (−9.08, 38.36)
Pseudomonas aeruginosa CAZ-NS 1 1 (100) 0 0 –
CAZ-S 10 10 (100) 14 12 (85.7) 14.3 (−16.23, 40.56)
a Difference in clinical cure rates (%).
b 95% conﬁdence interval (CI) for group differences was calculated using the unstratiﬁed Miettinen & Nurminen method. Clinical cure rate for the eME population was
deﬁned as the number of subjects with a response of clinical cure at the test-of-cure visit divided by the number of subjects with clinical cure + clinical failure. Clinical
response was based on surgical review evaluation if it was different from the investigator’s assessment. Ceftazidime resistance includes both the Clinical and Laboratory
Standards Institute breakpoint-deﬁned non-susceptible and intermediate categories [24]. Percentages are based on the total number of subjects in the subgroup (n).
Table 4
Safety evaluation up to late-follow-up visit (42–49 days after randomisation) (safety
population) [n (%)]a.
Ceftazidime/
avibactam +
metronidazole
(n = 215)
Meropenem
(n = 217)
AEs in ≥2% subjects in either treatment group by system organ class/preferred
termb [n (%)]
Nervous system disorders 7 (3.3) 6 (2.8)
Headache 3 (1.4) 5 (2.3)
Respiratory disorders 13 (6.0) 16 (7.4)
Productive cough 5 (2.3) 6 (2.8)
Cough 3 (1.4) 8 (3.7)
Gastrointestinal disorders 41 (19.1) 26 (12.0)
Nausea 18 (8.4) 4 (1.8)
Diarrhoeac 13 (6.0) 16 (7.4)
Constipation 5 (2.3) 3 (1.4)
Vomiting 5 (2.3) 4 (1.8)
General disorders 15 (7.0) 17 (7.8)
Pyrexia 9 (4.2) 13 (6.0)
Safety topicsd
Liver disorder 6 (2.8) 10 (4.6)
Diarrhoea 13 (6.0) 16 (7.4)
Hypersensitivity/anaphylaxis disorder 7 (3.3) 8 (3.7)
Haematological disorder 2 (0.9) 1 (0.5)
Renal disorder 1 (0.5) 1 (0.5)
AE, adverse event.
a Subjects with multiple AEs are counted once for each system organ class and/
or preferred term.
b AEs are sorted by system organ class in international order and by preferred term
in decreasing order of frequency in subjects treatedwith ceftazidime/avibactam +met-
ronidazole.
c No cases of Clostridium diﬃcile enterocolitis reported.
d Each safety topic represents the aggregate of a group of pre-identiﬁed relevant
AE preferred terms based on those from previous a phase 2 study of ceftazidime/
avibactam in complicated intra-abdominal infection.
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mMITT population in a previous study carried out in Western sub-
jects [18]. Whilst this discrepancy compared withWestern subjects
may be seen as a potential limitation of the study, we believe the
conclusions are still valid, and the overall susceptibility proﬁle of
the study population allowed for the assessment of the utility of
ceftazidime/avibactam both against ceftazidime-non-susceptible and
ceftazidime-susceptible pathogens.
In the present study, there were lower MICs for ceftazidime/
avibactam against ceftazidime-non-susceptible isolates compared
with ceftazidime alone, and all ceftazidime-non-susceptible En-
terobacteriaceae and P. aeruginosa isolates had a ceftazidime/
avibactamMIC ≤ 8mg/L, indicating that avibactam effectively restored
the in vitro activity of ceftazidime against ceftazidime-non-
susceptible isolates in line with previous data [11–13]. With regard
to clinical outcome in the ceftazidime/avibactam plus metronida-
zole treatment group, the proportion of subjects who had
ceftazidime-non-susceptible Enterobacteriaceae infections andwere
recorded as clinical cure at the TOC visit in the eME population was
comparable with that of subjects with ceftazidime-susceptible En-
terobacteriaceae infections (95.2% vs. 91.4%, respectively), providing
further evidence for the clinical utility of ceftazidime/avibactam
against ceftazidime-non-susceptible pathogens.
No new safety concernswere identiﬁed for ceftazidime/avibactam
in this study. The majority of AEs were mild or moderate in inten-
sity with a low incidence of discontinuations due to AEs, and there
were no deaths that were considered related to the study drugs. Al-
though these data only represent a subset of patients from Asia, they
add to the overall safety database of the use of ceftazidime/
avibactam in patients with cIAI. Furthermore, taking into account
the known safety proﬁle of metronidazole, safety ﬁndings for
ceftazidime/avibactam in this study were in line with other popu-
lations and the known proﬁles of ceftazidime and cephalosporins
in general [33].
To conclude, ceftazidime/avibactam plusmetronidazole was non-
inferior to meropenem in the treatment of patients with cIAI in
China, the Republic of Korea and Vietnam, with a safety proﬁle re-
ﬂective of ceftazidime alone. In addition, ceftazidime/avibactam plus
metronidazole was effective against ceftazidime-non-susceptible En-
terobacteriaceae. These data support the use of ceftazidime/
avibactam plus metronidazole as a potential treatment option for
subjects in Asia with cIAI, including those infected with ceftazidime-
non-susceptible pathogens.
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